Mipletamig
(AML)
CD3 T cell Engager Targeting CD123 Tumor Antigen on Hematologic Malignancies
ALG.APV-527
(Solid Tumors)
5T4 Tumor Antigen Dependent 4-1BB Costimulator
APVO603
(Solid Tumors)
Dual TNFR Co-stimulator Targeting 4-1BB/OX40
APVO711
(Solid Tumors)
Dual MOA blocking the PD-1/PD-L1 pathway while providing CD40 costimulation to APC
APVO442
(Prostate Cancer)
APVO455
(Solid Tumors)
Low Affinity CD3 T Cell Engager Targeting the Tumor-Associated Antigen (TAA) PSMA on Prostate Cancer
CD3 T Cell Engager Targeting the TAA Nectin-4 on Various Solid Tumors
APVO451
(Solid Tumors)
APVO452
(Prostate Cancer)
APC costimulation and CD3 T cell Engager Targeting the TAA Nectin-4
APC costimulation and CD3 T cell Engager Targeting the TAA PSMA
Aptevo: Developing Meaningful Therapeutics that Produce Promising Outcomes in the Fight Against Cancer
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for the treatment of cancer. Aptevo is seeking to improve treatment outcomes and transform the lives of cancer patients.